A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults
Paediatrics
A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults
Paediatrics

A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults

J Infect Dis. 2025 Nov 28:jiaf571. doi: 10.1093/infdis/jiaf571. Online ahead of print.

ABSTRACT

This study of a measles-vectored vaccine for chikungunya virus (MV-CHIK) was a Phase 1 randomized, double-blinded, placebo-controlled trial with varying intervals between the 2 doses. The 6 cohorts each had 30 subjects, of which 25 received MV-CHIK and 5 received placebo. The 5 × 105 TCID50 dose was superior to the 5 × 104 TCID50 dose, and longer dosing intervals resulted in higher titers in the high dose groups. Mild to moderate injection site and systemic reactogenicity was common but brief. There was no evidence of prolonged vaccine-related arthralgia.

PMID:41313671 | DOI:10.1093/infdis/jiaf571